logo-loader

Ergomed Plc adds to co-development pipeline with Allergy Therapeutics deal

Published: 02:25 14 Dec 2017 AEDT

Andrew Mackie, chief business officer at Ergomed Plc (LON:ERGO), caught up with Proactive to discuss their co-development agreement with Allergy Therapeutics plc (LON:AGY).

Under the terms of the collaboration, Ergomed will take the treatments for dust mite, tree pollen and grass pollen allergies through the clinic.

Ergomed's PeproStat successfully completes Phase II clinical trial

Andrew Mackie, chief business officer for Ergomed  PLC (LON:ERGO), tells Proactive they've successfully completed the Phase II clinical trial of their PeproStat blood thickening agent. Mackie adds the  coagulant met the primary endpoint over standard of care (SOC) in time to haemostasis –...

on 23/10/17